Vaccine stands for a preparation of dead, attenuate or else modified viruses, bacteria and other microorganisms utilized as an inoculation to immunize against any disease by way of stimulating antibodies’ production. With constant technology upgrades and launches of new medicinal products, Vaccines proved to be the most sophisticated healthcare aid ever created in the pharma’s history.
The global Vaccine Industry is thriving mainly owing to the chronic availability of different diseases, both already-existing and cropping up on the horizon, which can be luckily prevented with Vaccines’ assistance. Pediatric Vaccines form the largest and the most hastily evolving segment as against adult Vaccines, with the trend predicted to stay unaltered in the impending period. The worldwide Vaccine Market is primarily in the paws of such behemoths as Merck & Company, Inc.; Novartis, Pfizer, Inc.; GlaxoSmithKline plc; and Sanofi Pasteur.
The research reports under this Catalogue provide in-depth assessments of the global Vaccine Industry, discussing pressing market issues and statistical figures. The research reports cover the sizing (value/volume) and short-to-long-run forecasts for the overall Vaccine Market and its major segments, and for numerous geographic markets. The listing of M&As among the Vaccine universe participants with new products’ reviews, alongside company profile information can be derived from the research reports too.
Publications found:
915
Sort by:
HIV Vaccine Market Opportunity & Clinical Pipeline Analysis
US$ 2,000.00
... promising. “HIV Vaccine Market Opportunity & Clinical Pipeline Analysis” Report Highlights: Introduction to HIV Vaccine & Mechanism Global HIV Incidence Scenario R&D Funding Scenario for HIV Vaccine FDA Regulatory Framework HIV Vaccine Clinical Trial by Phase & Country HIV Vaccines in Development Phase ...
March 2014
330 pages
US Cancer Vaccine Pipeline Analysis
US$ 1,500.00
... for entry. Constituting almost 50% of the global pie, the US cancer vaccine market was estimated to be worth USD 14 Billion in 2012. With close ... cancer every year, this market is expected to o reach USD 20 billion by 2020. “US Cancer Vaccine Pipeline Analysis” by PNS Pharma gives comprehensive insight on the ...
January 2014
300 pages
Global Vaccine Market Pipeline Analysis
US$ 1,500.00
... sub-divided into four groups namely, pediatrics, adolescents, adults and elderly. Though the vaccines segment forms a very small portion of the ... market is expected to surpass estimated USD 100 billion by 2025. “Global Vaccine Market Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ...
January 2014
1150 pages
Global DNA Vaccine Pipeline Analysis
US$ 1,500.00
... West Nile Virus to be used in horses was approved in 2005. 'Global DNA Vaccine Pipeline Analysis' by PNS Pharma gives comprehensive insight on the various ... holders to identify and analyze the available investment opportunity in the DNA vaccine market based upon development process. Following parameters for ...
October 2013
130 pages
Research Report on China Measles, Mumps and Rubella (MMR) Vaccine Market, 2013-2017
US$ 1,200.00
... (incidence rate: below 1/100,000,000). In 2012, China's lot released volume of measles vaccines reached 8.651 million person-servings, decreasing ... vaccines manufactured by Merck violated the approval process of imported vaccines in China because it lacked alerts in the specification and existed safety risks. ...
September 2013
20 pages
Research Report on China Human Rabies Vaccine Industry, 2013-2017
US$ 1,200.00
... , but the rabies vaccination rate of dogs is less than 10%. Second, China lacks a coordination and management mechanism among departments involving in rabies ... the following information or even more: Development environment of China human rabies vaccines China rabies status overview Supply and demand status ...
September 2013
20 pages
Research Report on China's Haemophilus Influenza B (HIB) Vaccine Industry, 2013-2017
US$ 1,200.00
... influenza type B is a kind of haemophilus influenza with extremely strong invasiveness. Among all the serious infections caused by haemophilus influenzas, almost 90% were caused by haemophilus influenza type B. According to the researches in recent years, HIB has become the first bacteria that will cause ...
August 2013
20 pages
Research Report on Global and China Human Vaccine Industry, 2013-2017
US$ 2,200.00
... Type B Haemophilus Influenzae Conjugate Vaccine, Influenza Vaccine, Rabies Vaccine and so on. In China, Vaccine I market are occupied by state-owned enterprises, while foreign- ... market will rise continually. Due to the low vaccination rate in China, there's much space for future growth. With the increase of ...
August 2013
50 pages
Competitor Analysis: Anthrax Vaccines & Therapeutics
US$ 257.00
The Competitive Intelligence Report Anthrax Vaccines & Therapeutics as of June 2013 provides a competitor analysis in the development pipelines of novel vaccines and therapeutics for prophylaxis of Bacillus anthracis infection and treatment of anthrax. Purchase of the pdf report includes a 6-month online ...
June 2013
32 pages
Vaccines - Ireland
US$ 653.00
... perspective on the actual market situation, trends and future outlook for vaccines in Ireland. The study provides essential market information for decision- ... market study answers to questions such as: What is the size of the vaccine market in Ireland? How is the market divided into different types of products ...
May 2013
19 pages
Vaccines - Panama
US$ 653.00
... perspective on the actual market situation, trends and future outlook for vaccines in Panama. The study provides essential market information for decision- ... market study answers to questions such as: What is the size of the vaccine market in Panama? How is the market divided into different types of products? ...
May 2013
19 pages
Vaccines - Global Markets Package
US$ 24,090.00
... as: What is the size of the vaccine markets in different countries around the world? How are the markets divided into different types ... Years covered: 2006 - 2017 Countries included in the package: Argentina, Armenia, Australia, Austria, Azerbaijan, Bangladesh, Belgium, Bolivia, Bulgaria, Canada, Chile, ...
May 2013
1406 pages
Vaccines - Mongolia
US$ 653.00
... a perspective on the actual market situation, trends and future outlook for vaccines in Mongolia. The study provides essential market information for decision- ... study answers to questions such as: What is the size of the vaccine market in Mongolia? How is the market divided into different types of products? ...
May 2013
19 pages
Vaccines - Top 10 Global Markets Package
US$ 5,180.00
... a perspective on the actual market situation, trends and future outlook for vaccines in the top 10 global countries. The studies provide essential market ... These market studies answer to questions such as: What is the size of the vaccine markets in top 10 global countries? How are the markets divided into ...
May 2013
190 pages
Global Vaccine Market
US$ 653.00
... indicators This market study answers to questions such as: What is the size of the global vaccine market? How is the market divided into different types of products? Which products are growing fast? How the market has been developing? How does the future look like? What is the ...
May 2013
19 pages
Vaccines - American Markets Package
US$ 5,180.00
This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different American countries. The studies ... different types of products? Which products are growing fast? How the markets have been developing? How does the future look like? ...
May 2013
190 pages
Competitor Analysis: Human Papilloma Virus (HPV) Vaccines & Therapeutics
US$ 322.00
The Competitive Intelligence Report Human Papilloma Virus (HPV) Vaccines & Therapeutics as of May 2013 provides a competitor analysis in the product portfolios and development pipelines of novel vaccines and therapeutics for prophylaxis of HPV infection and HPV-induced neoplasias and treatment of HPV-induced ...
May 2013
43 pages
Global Vaccine Market Forecast to 2017
US$ 1,500.00
... and operating incomes amidst patent cliffs of blockbuster drugs. In such a scenario, vaccines, which have high entry barriers for generic players and ... with high incidence rates of infectious diseases. The report, “Global Vaccine Market Forecast to 2017” provides an extensive research and in-depth analysis ...
April 2013
125 pages
Vaccine Manufacturing Technology and Services: World Market 2013-2023
US$ 2,400.00
... revenues to 2023. It explains trends, opportunities and prospects for those technologies.а Our study lets you assess sales data at overall world ... and commercial possibilities. Eight ways Vaccine Manufacturing Technology and Services: World Market 2013-2023 helps In particular, then, our investigation ...
January 2013
194 pages
Competitor Analysis: Herpes Virus Vaccines and Therapeutics
US$ 396.00
... infect humans. HSV-1 and HSV-2 cause the viral disease herpes simplex which can be categorized into one of several distinct disorders ... . In addition, the report lists company-specific R&D pipelines of Herpes Virus Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information ...
December 2012
56 pages
Indian Vaccine Industry: Trends & Opportunities (2012-2017)
US$ 800.00
... Indian Vaccine Industry: Trends and Opportunities (2012-2017) offers in-depth study of the global as well as the Indian vaccine industry with detailed discussion on the major segments of the vaccine industry ...
November 2012
62 pages
Competitor Analysis: Pneumococcal and Streptococcal Vaccines
US$ 260.00
... , Company, Product Category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, ...
October 2012
21 pages
Vaccines 2012 World Market Analysis, Key Players, Trends, Pediatric and Adult Segments
US$ 3,995.00
... past year, and these are covered in this report Vaccines 2012: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing ... elderly populations. This report includes profiles of the key players in vaccines, including: AlphaVax, Inc. Bavarian Nordic A/S Baxter Healthcare Bharat Biotech ...
September 2012
249 pages
Competitor Analysis: Tuberculosis Vaccines and Therapeutics
US$ 516.00
... targeting Mycobacterium tuberculosis for prophylaxis and treatment of tuberculosis. In addition, the report lists corporate and public R&D pipelines of Tuberculosis Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action ...
September 2012
70 pages
Competitor Analysis: Malaria Vaccines & Therapeutics
US$ 390.00
... description The present Competitive Intelligence Report about Malaria Vaccines & Therapeutics provides a competitor evaluation in the field of investigational small molecules and ... regions. Each year more than 350 million new cases of Malaria occur, it is one of the world’s most common diseases. People with ...
August 2012
64 pages
Competitor Analysis: CMV Vaccines & Therapeutics
US$ 247.00
... approved for treatment or prevention of CMV disease, such as ganciclovir, or hyperimmune globulin preparations, but no specific CMV vaccine is approved. The present Competitor Analysis describes the R&D pipeline of new molecular entities including vaccines, monoclonal antibodies, peptides, cellular therapy ...
August 2012
23 pages
World Vaccines Market 2012-2022
US$ 2,635.00
... and branded groups - including Prevnar-13, Pentacel, Gardasil and Fluzone - perform to 2022? Our investigation shows business research and analysis with sales ... receive 91 tables, 63 charts and a research interview. Eight ways World Vaccines Market 2012-2022 helps you In particular, our study gives you ...
July 2012
199 pages
Competitor Analysis: Dengue Virus Vaccines and Therapeutics
US$ 243.00
... of Dengue fever and of therapeutics for treatment of Dengue fever. In addition, the report lists company-specific R&D pipelines of Dengue Virus Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, ...
July 2012
27 pages
Competitor Analysis: RSV Vaccines and Therapeutics
US$ 315.00
Competitor Analysis: Respiratory Syncytial Virus (RSV) Vaccines and Therapeutics The present Competitive Intelligence Report about RSV Vaccines & Therapeutics provides a ... RSV disease in infants and children at high risk for severe lung disease from RSV, a RSV vaccine still is not on the market. A number ...
June 2012
30 pages
Hepatitis Treatments and Vaccines: World Market 2012-2022
US$ 2,635.00
... all-oral, interferon-free regimens with improved efficacy over present treatments. Companies are developing oral antiviral combinations, with launches expected ... 80 tables, 64 charts and a research interview. Eight ways Hepatitis Treatments and Vaccines: World Market 2012-2022 helps you In particular, our ...
May 2012
183 pages
Competitor Analysis: Pseudomonas Aeruginosa Vaccines and Therapeutics
US$ 394.00
The present Competitive Intelligence Report about Pseudomonas aeruginosa Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, peptides and small molecules as well as DNA-, RNA- and microorganism-based therapies against infection with ...
May 2012
46 pages
Research Report on Chinese Human Vaccine Industry, 2012
US$ 3,000.00
The research object of the report is human vaccine apart from animal vaccine. Vaccination is the most economical, effective, safe and convenient way to prevent disease and the investment of vaccinatio...
March 2012
50 pages
Vaccine Pipeline Database: 1-Year Subscription
US$ 1,333.00
Subscription to La Merie’s proprietary Vaccine Pipeline Database provides online access to more than 1,200 project entries for prophylactic and therapeutic vaccines on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use ...
October 2011
274 pages
Competitor Analysis HIV Vaccines
US$ 413.00
... (plasmid, conventional, alternative delivery and prime – boost regimens) Adenoviral vector vaccines Poxvirus vector vaccines Protein & peptide vaccines Others Corporate HIV Vaccine R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise ...
October 2011
54 pages
Competitor Analysis: Hepatitis Vaccines
US$ 498.00
... Vaccines Combination Vaccines including HAV Vaccines Combination Vaccines including HBV Vaccines Hepatitis C Virus Vaccines Hepatitis E Virus Vaccines Corporate Hepatitis Vaccine Product Portfolios and R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but ...
June 2011
96 pages
Competitor Analysis Influenza Vaccines
US$ 718.00
... of seasonal and pandemic influenza disease. In addition, the report lists company-specific product portfolios and R&D pipelines of influenza vaccines on the market and in R&D. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of ...
May 2011
123 pages
Asian Vaccine Markets
US$ 3,500.00
The Asian vaccines market is relatively small compared to its population, yet it is growing, and pharmaceutical manufacturers increasingly will look to boost sales from these emerging vaccine markets....
March 2011
180 pages
World Influenza Vaccines Market 2011-2021
US$ 2,325.00
... left behind Our new report gives you revenue forecasts, growth rates, market share analysis, SWOT analysis, an R&D review and expert opinion. We include 132 ... charts and four interviews (shown in the accompanying lists). World Influenza Vaccines Market 2011-2021 shows you revenue trends, opportunities and ...
February 2011
216 pages
Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report
US$ 2,649.00
... Biosciences presents a comprehensive industry analysis of the cancer vaccines space as well as that of the emerging circulating tumor cells (CTCs) space. These two ... This report also examines the technology and market landscape for circulating tumor cells (CTCs). There is currently much interest in CTCs as they ...
December 2010
139 pages